Videos
Multiple myeloma patients and the COVID-19 Delta variant
In This COVID-19 FAQ episode, myeloma expert Dr. Brian G.M. Durie discusses how myeloma patients can best protect themselves against the Delta variant.
The BOTTOM LINE:
Continue to practice safety recommendations, including mask…
Videos
Phase III Tourmaline - MM1 Study
Background of the study:
Despite an increasing number of treatment options for relapse/refractory multiple myeloma, there remains a need for efficacious and tolerable therapies for patients who are refractory to treatment or continue to…
Videos
ICARIA Multiple Myeloma Phase III Study
Background of the study:
Isatuximab (Isa) is an approved monoclonal antibody that binds to a specific epitope on the CD38 receptor. The Phase 3 ICARIA-MM study (NCT02990338) demonstrated significantly improved progression-free survival…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the MN, WI, MI region.This International Myeloma Foundation Regional Community Workshop virtual offers myeloma patients and caregivers up-to-the-minute information…
Videos
Dr. Sagal Lonial on an Iberdomide Combination Therapy
In this video:
Iberdomide (IBER) is an oral, novel cereblon E3 ligase modulator (CELMoD) compound with marked synergistic tumoricidal and immune-stimulatory effects in combination with proteasome inhibitors (PIs) or anti-…
Audio
In this episode of “A Day in the Life” podcast, we're talking to Peter Smith, a seven-year myeloma survivor, accomplished educator, author, and now, prolific painter. Listen to the full interview. Then, scroll down to the bottom of this page to view an online gallery of a few of Peter's paintings…
Videos
Dr. Aurore Perot on the ICARIA-MM Phase III Study
Background of the study:
Isatuximab (Isa) is an approved monoclonal antibody that binds to a specific epitope on the CD38 receptor. The Phase 3 ICARIA-MM study (NCT02990338) demonstrated significantly improved progression…
Videos
Belantamab Mafodotin and Ocular Issues
Background of the study:
Belantamab mafodotin (GSK2857916; belamaf; BLENREP) is a B-cell maturation antigen (BCMA)-targeting antibody–drug conjugate approved in the US and by the European Union (EU) as a monotherapy for the…
Videos
Dr. Thierry Facon on Results of the MAIA Study
Background of the study:
The primary analyses of the phase III ALCYONE, MAIA, and CASSIOPEIA studies established the superior clinical efficacy of daratumumab (DARA) in combination with standard-of-care regimens versus standard…
Videos
Dr. Evangelos Terpos on the APOLLO Study
Background of the study:
APOLLO is a phase III trial of pomalidomide and dexamethasone (Pd) ± subcutaneous daratumumab (1800 mg, co-formulated with recombinant human hyaluronidase PH20 in 15 mL) in patients with…
Videos
Dr. Cristina Gasparetto on the Results of Once-weekly Xpovio (selinexor), Kyprolis (carfilzomib), and dexamethasone, or (XKd)
Background of the Study:
Exportin 1 (XPO1) mediates the nuclear export and functional inactivation of tumor suppressor proteins (TSPs), is associated…
Videos
Dr. Evangelos Terpos on the Results of the DARIA Study
Background of the study:
Second-line treatment of patients (pts) with multiple myeloma (MM), who are refractory to, or have relapsed after frontline lenalidomide-based therapy is challenging. Daratumumab (DARA), an anti-…
Videos
Dr. Heinz Ludwig on the UVEA IXA Study
Background of the study:
In multiple myeloma treatment, it is important to improve our understanding of routine clinical practice and the effectiveness of new agents outside of clinical trials. Ixazomib (Ixa) is approved for MM…
Audio
Diagnosed in 2015, Kevin Veenstra shares how he has coped with living with multiple myeloma.
Transcript:
Videos
click on the image above to view the replayVirtual Myeloma Webinar Focusing on Communities in the Southwest U.S. RegionWhat is included in the Regional Community Webinar?This International Myeloma Foundation Regional Community Workshop offers myeloma patients and caregivers up-to-the-…
Audio
In this episode of “A Day in the Life” podcast, Robert Pugh, a retired businessman, pastor, and father of four grown children, shares his story. In 2014, Robert was preparing to run in a 15k race. Even though he had no symptoms, a routine physical examination revealed a decline in his white blood…
Videos
Dr. Albert Oriol on the Updated KarMMa Trial Results
What is the background of the study?
Patients with relapsed and refractory multiple myeloma (RRMM) previously exposed to immunomodulatory agents, proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs) have…
Videos
Dr. Bruno Paiva on the Tourmaline-MM3 and -MM4 Trials
What is the background of the study?
MRD status is the most powerful prognostic factor in newly diagnosed multiple myeloma and sustained MRD negativity is a surrogate for prolonged survival. Interest is growing for…
Videos
Dr. Hartmut Goldschmidt on the CARTITUDE-1 Study
What is the background of the study?
Patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed to immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs) and anti-CD38 monoclonal antibodies…
Videos
Dr. Katja Weisel on Cilta-Cel Versus the Standard of Care in the CARTITUDE-1 Study
What is the background of the study?
Triple-class exposed relapsed/refractory multiple myeloma (RRMM) patients (ie, those exposed to a proteasome inhibitor [PI], immunomodulatory drug [IMiD],…
News Article
Los Angeles, CA, June 15, 2021—The International Myeloma Foundation (IMF) congratulates the recipients of the 2021 IMWG Awards, given annually by the International Myeloma Working Group, a research division of the IMF. The awards…
Videos
Dr. Katja Weisel on Cilta-Cell Versus Belantamab Mafodotin
What is the background of the study?
Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) is a chimeric antigen receptor (CAR) T-cell therapy with two BCMA–targeting, single-domain antibodies designed to confer…
Videos
Dr. Nizar Bahlis on Elranatamab
What is the background of this study?
Elranatamab (PF-06863135) is a humanized bispecific monoclonal antibody (IgG2a) that targets BCMA, a member of the tumor necrosis factor receptor superfamily expressed in MM, and CD3 on T cells.…
Videos
Dr. Joseph Mikhael on 2021's Top Myeloma-Related ASH and EHA Abstracts
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope Cancer Center – Scottsdale, AZ, USA) provides an overview of the top myeloma-related abstracts from the 2021 American Clinical Society of…
Videos
Dr. Katja Weisel on the GMMG-CONCEPT Trial
What is the background of the study?
As high-risk (HR) multiple myeloma (MM) patients (pts) still have a significantly impaired prognostic outcome, there is an unmet clinical need for potent therapeutic strategies already in front-…
Videos
Dr. Neils van de Donk Discusses a Phase I Teclistamab Study
What is the background of the study?
B-cell maturation antigen (BCMA)-targeted immunotherapies are promising treatment options for patients with relapsed/refractory multiple myeloma. Teclistimab (JNJ-64007957) is a…
Videos
Dr. Ankit Kansagra Discusses the Cost-Effectiveness of Belantamab Mafodotin and Selinexor
What is the background of this study?
Highly effective drugs have significantly affected the outcomes of multiple myeloma, with a five-year survival improving from 34.6…
Videos
Dr. Saad Usmani on a Study of Cilta-Cel Safety
What is the background of this study?
CARTITUDE-1 (NCT03548207) is a phase Ib/II study evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA–targeting single-domain antibodies,…
Videos
What is the background of this study?
“High-risk (R-ISS stage III) newly diagnosed multiple myeloma (NDMM) has a poor prognosis with a median progression-free survival of 29 months. According to Dr. Antonio Palumbo, this highlights the need for novel disease-targeting…
Videos
Dr. Hermann Einsele Discusses the Results of the CARTITUDE-2 Study
What is the background of the study?
Cilta-cel (JNJ-68284528) is a chimeric antigen receptor T (CAR-T)-cell therapy with 2 BCMA-targeting, single-domain antibodies designed to confer high avidity binding.…
Videos
Dr. Salomon Manier on Neurotoxicity As Seen in the KarMMa Study
What is the background of this study?
In the KarMMa study, ide-cel, a BCMA-directed CAR T cell therapy, showed promising efficacy in patients with relapsed refractory multiple myeloma. It had an overall…
Videos
Dr. Maria-Victoria Mateos on the LIGHTHOUSE Study
What is the background of this study?
Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that leverages aminopeptidases and rapidly releases alkylating agents inside tumor cells. Melflufen…
Videos
Dr. Luciano Costa on a Cilta-Cel Study
What is the background of this study?
CARTITUDE-1 is “a single arm study of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients with relapsed multiple myeloma (RRMM) refractory to both…
Videos
Dr. Maria-Victoria Mateos Reports on Interim Results of the LocoMMotion Study
What is the background of this study?
Despite improvements in myeloma care, the disease remains incurable. most patients with myeloma eventually progress through standard drug classes of…
Videos
Dr. Luciano Costa on the Phase I/II EVOLVE Study
What is the background of this study?
Orva-cel is a B-cell maturation antigen–targeted chimeric antigen receptor (CAR) T cell therapy being evaluated in the phase I/II EVOLVE study (NCT03430011) in pateints with relapsed…
Videos
Dr. Thomas Martin on Cilta-Cel in the CARTITUDE-1 Study
What is the background of this study?
Patients with relapsed refractory multiple myeloma (RRMM) who are triple-class exposed (to immunomodulatory drugs [IMiDs], proteasome inhibitors [PIs] and an anti-CD38 antibody…
Videos
Dr. Philippe Moreau on the CASSIOPEIA - Part 2 Study
What is the background of the study?
Daratumumab (DARA) and Velcade (bortezomib)/thalidomide/dexamethasone (DVTd) plus autologous stem cell transplant (ASCT) was approved for transplant-eligible (TE) newly…
Videos
Dr. Kwee Young on the CARDAMON Study
What is the background of the study?
Upfront autologous stem cell transplant (ASCT) for newly diagnosed, transplant-eligible multiple myeloma patients remains under evaluation with high MRD rates following novel induction…
Videos
Dr. Martin Frasier on the iTIMM Study
What is the background of this study?
Early and sensitive detection of bone marrow disease and stratified patient management according to clinical risk can confer survival advantages in multiple myeloma (MM). Whole body MRI (WB MRI) and…
Videos
Dr. Xavier Leleu on the BOSTON Trial
What is the background of this study?
Lenalidomide (LEN) is typically a frontline therapy for newly diagnosed multiple myeloma. Patients with multiple myeloma refractory to LEN are less likely to respond to other …
Videos
Dr. Mounzer Agha on the Phase II CARTITUDE-2 Study
What is the background of this study?
Cilta-cel is a CAR T-cell therapy expressing two BCMA-targeting, single-domain antibodies designed to confer avidity. The multicohort, phase II CARTITUDE-2 study (NCT04133636) evaluates…
Videos
Dr. Martin Kaiser on the OPTIMUM/MUKnine Trial
What is the background of this study?
Patients with ultra high-risk (UHiR) newly diagnosed multiple myeloma (NDMM) and patients with plasma cell leukemia (PCL) continue to have dismal outcomes and are underrepresented in…
Videos
Dr. Francesca Gay on the FORTE Study
What is the background of this study?
Cytogenetic abnormalities (CA) are one of the most powerful prognostic factors in multiple myeloma. In the FORTE study, carfilzomib-lenalidomide-dexamethasone induction/consolidation with ASCT (…
Videos
When should patients consider altering their treatment regimen?
In this episode, Dr. Brian G.M. Durie discusses if myeloma patients should change their treatment to a new CAR T-cell therapy even if their current treatment is still effective.
The BOTTOM LINE:
If the current treatment is…
Event
This International Myeloma Foundation Regional Community Workshop offers myeloma patients and caregivers up-to-the-minute information about multiple myeloma. Topics include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on…
Videos
Dr. Amrita Krishnan on a Phase I Teclistimab Study
What is the background of this study?
BCMA-targeted immunotherapies offer considerable promise for relapsed/refractory multiple myeloma (MM). Teclistamab (JNJ-64007957) is a BCMA × CD3 bispecific IgG4 antibody that…
Videos
Dr. Matthew J. Frigault on a Phase 1 Study of CART-ddBCMA,
What is the background of this study?
CART-ddBCMA is an autologous CAR-T cell therapy encoding a novel non-scFv synthetic binding domain targeting BCMA with a 4-1BB costimulatory motif and CD3-zeta T-cell…
Videos
Dr. Efstathios Kastritis on the Phase III ADROMEDA Study
What is the background of the study?
Systemic AL amyloidosis is a plasma cell disease characterized by the deposition of insoluble amyloid fibrils causing organ dysfunction and death. Primary results from the ANDROMEDA…
Videos
Dr. Roman Hajek Discusses the IKEMA Subgroup Analysis
What is the background of this study?
Patients (pts) with multiple myeloma (MM) often relapse and become refractory to successive lines of therapy, warranting better treatment options. The Phase 3 IKEMA study (NCT03275285…